Table 2.
Comparison of treatment and prognosis of IgG4‐related sclerosing cholangitis
| Region | Year | n | Follow‐up period (months) | Corticosteroid treatment | Cirrhosis | All‐cause mortality | LT | Mortality due to liver and bile duct diseases | Ref |
|---|---|---|---|---|---|---|---|---|---|
| United States | 2008 | 53 | 29.5a | 30 (57%) | 4 (7.5%) | 7 (13%) | 0 | 1 (1.9%) | 16 |
| United Kingdom | 2014 | 68 | 32.5 | 98 (85%)b | 6 (5.2%)a | 11 (9.6%)a | 1 | 3 (2.6%)a | 58 |
| Japan | 2017 | 527 | 49.2 | 458 (88%) | N/A | 26 (5%) | 0 | 4 (0.8%) | 19 |
LT liver transplantation, N/A not available
a
The average follow‐up period of patients treated with corticosteroids
b
The proportion in 115 patients with autoimmune pancreatitis, including those without IgG4‐SC